A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. THE COMPANY Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs. Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States while we continue to build a network of international partners to register and provide our medicines to patients in their countries. Our portfolio of brands approved for marketing by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 45M | 45M | 38M | 40M | 42M | 36M |
| Net Income | -2.8M | -2.8M | -6.5M | -6.3M | -5.6M | -3.5M |
| EPS | $-0.19 | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 |
| Free Cash Flow | 4.8M | 4.8M | -679K | 5.8M | 8.4M | 6.2M |
| ROIC | -9.3% | -9.8% | -23.2% | -14.8% | -10.6% | -6.1% |
| Gross Margin | 43.5% | 43.5% | 39.7% | 31.7% | 78.3% | 75.5% |
| Debt/Equity | 0.41 | 0.41 | 0.90 | 0.62 | 1.02 | 0.73 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.8M | -2.8M | -6.4M | -9.6M | -5.7M | -7.7M |
| Operating Margin | -6.3% | -6.3% | -17.0% | -24.2% | -13.6% | -21.3% |
| ROE | -11.4% | -11.9% | -28.4% | -21.2% | -15.4% | -8.2% |
| Shares Outstanding | 15M | 15M | 14M | 14M | 15M | 15M |
CUMBERLAND PHARMACEUTICALS INC passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 6.9x vs a median of 9.8x. The company's 5-year average gross margin is 53.7%. Total shareholder yield (buybacks) is 0.6%. At current prices, the estimated annualized return to fair value is +14.3%.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a 5-year average return on invested capital (ROIC) of -12.9%. This is below average and may indicate limited pricing power.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a market capitalization of $47M. It is classified as a small-cap stock.
CUMBERLAND PHARMACEUTICALS INC (CPIX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.57%.
CUMBERLAND PHARMACEUTICALS INC (CPIX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CUMBERLAND PHARMACEUTICALS INC (CPIX) reported annual revenue of $45 million in its most recent fiscal year, based on SEC EDGAR filings.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a net profit margin of -6.4%. The company is currently unprofitable.
CUMBERLAND PHARMACEUTICALS INC (CPIX) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a debt-to-equity ratio of 0.41. This indicates a conservatively financed balance sheet.
CUMBERLAND PHARMACEUTICALS INC (CPIX) reported earnings per share (EPS) of $-0.19 in its most recent fiscal year.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a return on equity (ROE) of -11.9%. A negative ROE may indicate losses or negative equity.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a 5-year average gross margin of 53.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for CUMBERLAND PHARMACEUTICALS INC (CPIX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CUMBERLAND PHARMACEUTICALS INC (CPIX) has a book value per share of $1.67, based on its most recent annual SEC filing.